Furthermore, pharmacologic inhibition of STK25 with antisense oligonucleotides—administered systemically or hepatocyte-specifically—efficiently mitigated the development and exacerbation of hepatocarcinogenesis in a mouse model of MASH-driven HCC. Here, STK25 is linked to hepatocellular carcinoma.